A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme, Adult Clinical Trial

Official title:

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04762069
• Other study ID #: CNS-201
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 18, 2021
• Est. completion date: March 2025

Study information

• Verified date: June 2024
• Source: CNS Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.

Description:

Berubicin is one of the first anthracyclines that crosses the blood brain barrier and overcomes drug resistance (i.e. it is not a substrate for multi-drug resistant/breast cancer resistant transporters). A Phase 1 clinical trial of berubicin in patients with primary CNS malignancies demonstrated a durable response (one subject alive 13+ years) as well as stable disease in heavily pretreated patients. Therefore, this phase 2 study is designed to further evaluate Berubicin's activity in patients with rGBM after treatment with standard of care.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 210
• Est. completion date: March 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Patients will be eligible for the study if they meet all of the following inclusion criteria and none of the exclusion criteria. Inclusion criteria

1. Written informed consent from the patient or their legally authorized representative (LAR) prior to any study-related procedure, and willing and able to comply with the protocol and aware of the investigational nature of this study.

2. At least 18 years of age.

3. KPS score of = 60

4. A confirmed GBM diagnosis must be based on local review of tumor tissue from the initial biopsy, surgery, or re-resection. A formal pathology report confirming GBM is acceptable. It is not a requirement for slides to be sent to a central reviewer.

5. Recurrent or progressive GBM as evaluated by central review applying RANO criteria on contrast MRI scans of the Baseline/Screening MRI scan obtained up to six weeks prior to C1D1 and a historical scan taken before the Baseline/Screening scan that meets at

least 1 of the following criteria:

1. In the case of measurable disease, progression will be documented by = 25% increase in the sum of the perpendicular diameter products (SPDPs) of the measurable contrast-enhancing (target) lesions or any new measurable lesions.

2. If the SPDPs cannot be reliably estimated due to the lesion's complex conspicuity, shape, and contrast enhancement pattern, the volume of all measurable and non-measurable lesions may be used instead, applying the same threshold (= 25% increase) to confirm disease progression.

3. In the case of non-measurable lesions in the historical scan, any transformation into measurable lesions (=10 mm in both maximum perpendicular diameters) in the Baseline/Screening scan will be evidence of progression.

4. If there are only non-measurable (non-target) lesions in the Baseline/Screening scan, additional lesions/sites will be considered evidence of progression based on the historical scan. Patients with new cerebrospinal fluid (CSF) seeding will not be considered eligible.

5. If historical scans are unavailable, a radiology report of a scan taken before the Baseline/Screening scan documenting the SPDPs from a previous scan of the enhancing disease or its volume can be used by the central reviewer to assess eligibility if it demonstrates the quality standards and acquisition guidelines required.

6. If the scan obtained during standard of care (prior to initiation of formal clinical screening and patient enrollment) is being used as the Baseline/Screening scan and does not entirely conform to central reader quality standards and acquisition guidelines (ie, artifacts or missing sequences), this can be used for the purpose of inclusion if the central reader in discussion with the sponsor and PI agree it provides evidence based on standard clinical practices of recurrence or progression.

7. Patients at first progression who are treated by re-resection or biopsy to confirm progression do not require measurable disease at their post-operative screening scan as their Baseline/Screening scan. These patients must be medically stable after the procedure as assessed by the PI and have the Baseline/Screening scan available by 7 days before starting treatment.

6. The tumor is localized supratentorially with no leptomeningeal (local or distant), spinal or CSF metastases, and no ventricular invasion (explicit documentation of the disease progression that would be problematic in evaluating the efficacy of this drug).

7. O[6] methylguanine-DNA methyltransferase (MGMT) methylation status must be available; results of routinely used methods for MGMT methylation testing (eg, methylation-specific polymerase chain reaction or quantitative polymerase chain reaction) are acceptable.

8. No more than 1 prior line of treatment (eg, surgery followed by radiation with concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of treatment). In addition, treatment with tumor treating fields (TTFields; Optune) is acceptable if provided as first line therapy prior to progression or recurrence of disease.

9. A second debulking surgery, additional radiation or gamma knife surgery during the first line treatment or after progression, and for which the investigator does not suspect pseudoprogression is acceptable, as long as no chemotherapy or immunotherapy has been provided.

10. Recovery from toxicity/side effects of all prior therapy to Grade 1 or less, subject to the investigator's discretion, except for alopecia; the following time intervals

from previous treatments are required to be eligible:

1. 12 weeks from the completion of radiation (to reduce risk of pseudoprogression), unless progression is confirmed by biopsy

2. 4 weeks from the end of any previous of chemotherapy

3. 2 weeks from tumor biopsy if wound completely healed

4. 4 weeks from any major surgery (maximal debulking surgery, either gross total resection or partial resection), gamma knife surgery or significant traumatic injury. Any surgery incisions or wounds must be completely healed

11. A stable or decreasing dose of corticosteroids (or none) for brain edema for at least 5 days prior to baseline MRI and enrollment in the study to document disease progression such that changes in the MRI are not related to the use of corticosteroids.

12. Eligible for chemotherapy based on adequate bone marrow function and organ function within 2 weeks of study treatment as defined by the following laboratory guidelines,

subject to the investigator's discretion:

1. Hematopoietic function: total white blood cell (WBC) count =3 × 103/µL, absolute neutrophil count (ANC) =1.5 × 10³/µL, platelet count =75 × 10³/µL, hemoglobin =10 g/dL

2. Hepatic function: bilirubin =1.5 × × the upper limit of normal (ULN) (excluding Gilberts Syndrome, for which bilirubin must be =4 × ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × ULN, and alkaline phosphatase =2.5 × ULN

3. Renal function: serum creatinine =1.5 × ULN or for patients with creatinine levels above the ULN, estimated creatinine clearance of =60 mL/min, calculated using the Cockcroft-Gault equation35

4. Activated partial thromboplastin time (aPTT) =1.5 × ULN

13. Women of childbearing potential must agree to practice a highly effective method of contraception beginning at least 28 days before the start of treatment until at least 6.25 months after the last dose of study drug. Male study patients and their female sexual partners of childbearing potential must agree to practice a highly effective method of contraception starting from the time of informed consent until at least 3.5 months (no less than 104 days) after the last dose of study drug.

1. A woman of childbearing potential is defined as a woman who is not permanently sterilized or postmenopausal. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.

2. Women of childbearing potential must have a negative serum or urine pregnancy test at Screening.

3. A highly effective method of birth control is defined as one which results in a low failure rate (ie, less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. For patients using a hormonal contraceptive method, information regarding all medications being administered to the patient and their potential effects on the contraceptive should be addressed.

14. Patients with prior malignancies must be disease-free for =5 years. Curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; or prostate cancer as well as benign tumors that will not interfere with the treatment plan at the time of screening are allowed. Exclusion Criteria

1. Unable or not willing to comply with the protocol regulations.

2. Any additional chemotherapy (including but not limited to TMZ or immunotherapy) for recurrent or progressive GBM after a first line treatment.

3. Prior treatment with bevacizumab.

4. Prior treatment with lomustine.

5. Known to have an IDH mutation prior to enrollment

6. Screening/Baseline MRI showing a mass effect defined as significant compression of the ventricular system and/or a midline shift with associated clinical symptoms deemed inappropriate for the patient to enter a clinical trial. If there is otherwise asymptomatic compression and/or midline shift and the patient fulfills all other criteria, these patients are considered eligible.

7. Any condition (medical, social, psychological) that would prevent adequate information and follow-up, including but not limited to clinically relevant psychiatric disorders, legal incapacity, dementia, adults protected by law or altered mental status.

8. Presence of poorly controlled seizures, defined as occurring despite SOC or requiring hospitalization.

9. Prior anthracycline cumulative dose more than 550 mg/m2.

10. Heart disease:

1. LVEF <50%

2. Unstable angina

3. CHF with New York Heart Association (NYHA) classification of 3 or 4

4. Patients with baseline QT/QTc interval >480 msec, a history of additional risk factors for torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of long QT syndrome) and using concomitant medications that significantly prolong the QT/QTc interval

5. History of myocardial infarction within 12 months of enrollment

6. Severe arrhythmia not controlled by medication

11. Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg and/or diastolic BP >100 mmHg) sustained over 2 measurements.

12. Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of screening), or any other acute viral, bacterial, or fungal infection (testing not required unless symptomatic or suspected disease).

13. Patients with any other uncontrolled intercurrent medical conditions, including but not limited to diabetes mellitus or chronic obstructive pulmonary disease that have not been well controlled by medical management over the prior 3 months are ineligible unless approved by the sponsor.

14. Women who are lactating or breastfeeding

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme, Adult

Intervention

Drug:
• Berubicin
Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
• Lomustine
Lomustine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "alkylating agent.

Locations

Country	Name	City	State
France	Hopital Pierre Wertheimer	Lyon
France	Hopital de La Timone	Marseille
France	Institut de Recherche en Cancerologie de Montpellier	Montpellier
France	Hopital Pitie-Salpetriere	Paris
France	Institut de Cancerologie de l'Ouest	Saint-Herblain
France	nstitut Universitaire du Cancer de Toulouse-	Toulouse
France	Institut de Cancerologie Gustave-Roussy	Villejuif
Italy	Servizio Sanitario Regionale Emilia-Romagna - Azienda USL di Bologna - Ospedale Bellaria	Bologna
Italy	Istituto Clinico Humanitas	Milan
Spain	Hospital Universitari Germans Trias i Pujol	Badalona
Spain	Hospital Duran i Reynals	L'Hospitalet De Llobregat
Spain	Hospital Ramón y Cajal	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Regional Universitario de Malaga Carlos Haya	Málaga
Spain	Hospital Universitario Virgen Macarena	Sevilla
Switzerland	University Hospital Zurich	Zürich
United States	Piedmont Healthcare	Atlanta	Georgia
United States	Texas Oncology PA	Austin	Texas
United States	Tufts Medical Center	Boston	Massachusetts
United States	Roswell Park Cancer Center	Buffalo	New York
United States	Rush University Cancer Center	Chicago	Illinois
United States	Ohio State University	Columbus	Ohio
United States	Baylor Research Institute	Dallas	Texas
United States	Duke University School of Medicine	Durham	North Carolina
United States	HCA Healthcare Research Institute	Englewood	Colorado
United States	Hackensack Meridian Health	Hackensack	New Jersey
United States	Milton S. Hershey Medical Center	Hershey	Pennsylvania
United States	University of Texas Health Science Center at Houston	Houston	Texas
United States	Baptist MD Anderson Cancer Center	Jacksonville	Florida
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	University of Kentucky	Lexington	Kentucky
United States	University of Arkansas	Little Rock	Arkansas
United States	Southern California Permanente Medical Group	Los Angeles	California
United States	University of Wisconsin Hospital and Clinics	Madison	Wisconsin
United States	Baptist Miami	Miami	Florida
United States	Tulane Cancer Center Clinic	New Orleans	Louisiana
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University of California Irvine	Orange	California
United States	Rutgers University	Piscataway	New Jersey
United States	Providence Health	Portland	Oregon
United States	Mayo Clinic	Rochester	Minnesota
United States	Huntsman Cancer Center	Salt Lake City	Utah
United States	University of Califonia San Diego Moores Cancer Center	San Diego	California
United States	University of California San Francisco	San Francisco	California
United States	Saint John's Cancer Institute at Providence Saint John's Health Center	Santa Monica	California
United States	Swedish Medical Center	Seattle	Washington
United States	Atlantic Healthcare	Summit	New Jersey
United States	UMass (ACC) - Hollings Cancer Center (HCC)	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
CNS Pharmaceuticals, Inc.	Worldwide Clinical Trials

Countries where clinical trial is conducted

United States,  France,  Italy,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Karnofsky Performance Status	Evaluate changes in Karnofsky Performance Status (KPS) score between arms	Through study completion an average of 4 years.
Other	Evaluate changes in patient-reported outcomes	Evaluate changes in patient-reported outcomes between arms.	Through study completion an average of 4 years.
Other	Explore the effect of O[6] methylguanine-DNA methyltransferase (MGMT) methylation	explore the effect of O[6] methylguanine-DNA methyltransferase (MGMT) methylation status on response to berubicin and comparison of theses subsets between arms	Through study completion an average of 4 years.
Other	Impact of re-resection	Impact of re-resection on outcomes	Through study completion an average of 4 years.
Other	Use of bevacizumab	Use of bevacizumab between the arms.	Through study completion an average of 4 years.
Primary	Overall Survival	To assess the effect of berubicin compared with lomustine on overall survival (OS) in adult patients with GBM that has recurred or progressed after standard initial therapy	Through study completion an average of 4 years.
Secondary	Progression Free Survival	To assess the effect of berubicin on progression free survival per Response Assessment in Neuro-Oncology (RANO) criteria in patients with GBM after failure of standard first line therapy	Through study completion an average of 4 years.
Secondary	Event Free Survival	To assess the effect of berubicin on event free survival (EFS) defined as the length of time from the initiation of study drug administration to disease progression, death, or discontinuation of treatment for any reason (eg, toxicity, intolerance, disease-related conditions, or failure to respond)	Through study completion an average of 4 years.
Secondary	Overall Response Rate	To assess the effect of berubicin on overall response rates (ORR) in adult patients with GBM after failure of standard first line therapy	Through study completion an average of 4 years.
Secondary	Safety of the Recommended Phase 2 Dose of Berubicin	To assess the safety of the recommended Phase 2 dose of berubicin by the incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0.	From signing of informed consent until until 28 days after the last dose of berubicin and 42 days after the last dose of lomustine, or until the patient receives any additional therapy for their disease (whichever comes first).
Secondary	Plasma Pharmacokinetics Cmax	Maximum plasma concentration of Berubicin	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics tmax	Time from each dose to reach the maximum plasma concentration	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics AUC0-tau	Area under the plasma concentration-time curve from time 0 to Tau, where Tau is the dosing interval, calculated by the linear up/ linear down trapezoidal method	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics AUC0-last	Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration calculated by the linear up/log linear down trapezoidal method	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics AUC0-8	Area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC0-last and Clast/?z, where Clast is the last observed quantifiable concentration	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics t1/2	elimination half-life associated with the terminal slope (?z) of the log-linear drug concentration-time curve, calculated as ln(2)/?z	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics CL	apparent total body clearance	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics Vz	apparent volume of distribution	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics Css	Average concentration, calculated as the geometric mean of concentrations over the 72-hour dosing interval	Through study completion an average of 4 years.
Secondary	Plasma Pharmacokinetics Rac	The accumulation ratio calculated as AUC0-tau (3rd dose) / AUC0-tau (1st dose)	Through study completion an average of 4 years.